Literature DB >> 19395993

Surveillance procedures for patients with cervical carcinoma: a review of the literature.

Vanna Zanagnolo1, Lucas Ming, Angiolo Gadducci, Tiziano Maggino, Enrico Sartori, Paolo Zola, Fabio Landoni.   

Abstract

Cervical cancer is still one of the most common malignancies in women. Treatment of cervical cancer is very successful, especially in the early stage. However, some patients will experience recurrence. The primary purpose of follow-up programs is early detection of recurrence disease that should be more likely to be amenable to treatment, thereby improving the clinical outcome. Although, in the literature, most studies have shown that the surveillance programs did not improve the clinical outcome of patients with diagnosis of recurrence, this clinical practice is regarded as traditional management. The use of Papanicolaou tests to detect recurrent cervical cancer is not sufficiently justified. The assessment of tumor markers such as the squamous cell carcinoma antigen could be useful. Imaging techniques are important for the detection and assessment of recurrent disease. The role of chest x-rays in detecting asymptomatic recurrence in patients treated for cervical carcinoma remains controversial. Detection of a new abnormal mass or the changes in the size of a known lesion caused by cancer growth and the determination of the extent of recurrence with computed tomography and magnetic resonance imaging may provide clinical assistance in the selection of optimal therapy. The fluoro-2-deoxy-glucose-positron emission tomography for surveillance only show 80% of specificity and accuracy with negative predictive value of 100%. Integrated fluoro-2-deoxy-glucose-positron emission tomography/computed tomography provides precise anatomic localization of suspicious areas and, therefore, a better diagnostic interpretation with a possible impact on disease-free survival as well. In conclusion, our review confirms the need for prospective studies to compare the effectiveness of different follow-up regimens measuring overall survival and quality of life parameters as outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19395993     DOI: 10.1111/IGC.0b013e31819c9ffd

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.

Authors:  Roberto Angioli; Stella Capriglione; Giuseppe Scaletta; Alessia Aloisi; Andrea Miranda; Carlo De Cicco Nardone; Corrado Terranova; Francesco Plotti
Journal:  Tumour Biol       Date:  2015-11-03

2.  Helical tomotherapy in cervical cancer patients: simultaneous integrated boost concept: technique and acute toxicity.

Authors:  Simone Marnitz; Carmen Stromberger; Michael Kawgan-Kagan; Waldemar Wlodarczyk; Ulrich Jahn; Achim Schneider; Uwe Ulrich; Volker Budach; Christhardt Köhler
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

3.  Optimal cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance.

Authors:  Jinju Oh; Jin Young Bae
Journal:  Obstet Gynecol Sci       Date:  2018-04-23

4.  Diagnostic Strategies for Recurrent Cervical Cancer: A Cohort Study.

Authors:  Xiaopei Chao; Junning Fan; Xiaochen Song; Yan You; Huanwen Wu; Ming Wu; Lei Li
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

Review 5.  Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review.

Authors:  Zongyan Shen; Ang Qu; Ping Jiang; Yuliang Jiang; Haitao Sun; Junjie Wang
Journal:  Curr Oncol       Date:  2022-07-25       Impact factor: 3.109

6.  Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation.

Authors:  Jinju Oh; Hyun Joo Lee; Tae Sung Lee; Ju Hyun Kim; Suk Bong Koh; Youn Seok Choi
Journal:  Obstet Gynecol Sci       Date:  2016-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.